Teclistamab in Relapsed or Refractory Multiple Myeloma. Reply

N Engl J Med. 2022 Nov 3;387(18):1722-1723. doi: 10.1056/NEJMc2211969.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Antibodies, Bispecific* / therapeutic use
  • Antineoplastic Agents* / therapeutic use
  • Antineoplastic Combined Chemotherapy Protocols
  • Humans
  • Multiple Myeloma* / drug therapy
  • Neoplasm Recurrence, Local / drug therapy

Substances

  • Antineoplastic Agents
  • Antibodies, Bispecific